Related Experiment Video
Updated: May 20, 2025

Monitoring Breast Cancer Growth and Metastatic Colony Formation in Mice using Bioluminescence
Published on: November 5, 2021
LRPPRC confers enhanced oxidative phosphorylation metabolism in triple-negative breast cancer and represents a
Qiqi Xue1,2,3, Wenxi Wang1,2, Jie Liu2
1Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310024, China.
Background:
Triple-negative breast cancer (TNBC) is a highly malignant tumor that requires effective therapeutic targets and drugs. Oxidative phosphorylation (OXPHOS) is a metabolic vulnerability of TNBC, but the molecular mechanism responsible for the enhanced OXPHOS remains unclear. The current strategies that target the electronic transfer function of OXPHOS cannot distinguish tumor cells from normal cells. Investigating the mechanism underlying OXPHOS regulation and developing corresponding therapy strategies for TNBC is of great significance.
Methods:
Immunohistochemistry and sequencing data reanalysis were used to investigate LRPPRC expression in TNBC. In vitro and in vivo assays were applied to investigate the roles of LRPPRC in TNBC progression. RT-qPCR, immunoblotting, and Seahorse XF assay were used to examine LRPPRC's functions in the expression of OXPHOS subunits and energy metabolism. In vitro and in vivo functional assays were used to test the therapeutic effect of gossypol acetate (GAA), a traditional gynecological drug, on LRPPRC suppression and OXPOHS inhibition.
Results:
LRPPRC was specifically overexpressed in TNBC. LRPPRC knockdown suppressed the proliferation, metastasis, and tumor formation of TNBC cells. LRPPRC enhanced OXPHOS metabolism by increasing the expression of OXPHOS complex subunits encoded by the mitochondrial genome. GAA inhibited OXPHOS metabolism by directly binding LRPPRC, causing LRPPRC degradation, and downregulating the expression of OXPHOS complex subunits encoded by the mitochondrial genome. GAA administration suppressed TNBC cell proliferation, metastasis in vitro, and tumor formation in vivo.
Conclusions:
This work demonstrated a new regulatory pathway of TNBC to promote the expression of mitochondrial genes by upregulating the nuclear gene LRPPRC, resulting in increased OXPHOS. We also suggested a promising therapeutic target LRPPRC for TNBC, and its inhibitor, the traditional gynecological medicine GAA, presented significant antitumor activity.
Insights
Triple-negative breast cancer (TNBC) relies on enhanced oxidative phosphorylation (OXPHOS). Targeting LRPPRC with gossypol acetate (GAA) inhibits OXPHOS and suppresses TNBC progression, offering a new therapeutic strategy.
Area of Science:
- Molecular oncology
- Metabolic pathways in cancer
- Mitochondrial gene regulation
Background:
- Triple-negative breast cancer (TNBC) is aggressive with unclear metabolic vulnerabilities.
- Enhanced oxidative phosphorylation (OXPHOS) is a key metabolic feature of TNBC.
- Current OXPHOS targeting strategies lack specificity.
Purpose of the Study:
- To elucidate the molecular mechanism of enhanced OXPHOS in TNBC.
- To identify novel therapeutic targets and strategies for TNBC.
- To investigate the role of LRPPRC in TNBC progression and metabolism.
Main Methods:
- Immunohistochemistry and sequencing data analysis to assess LRPPRC expression.
- In vitro and in vivo assays to evaluate LRPPRC function in TNBC.
- Seahorse XF assay to measure OXPHOS and energy metabolism.
- Assessment of gossypol acetate (GAA) efficacy in LRPPRC suppression and OXPHOS inhibition.
Main Results:
- LRPPRC is overexpressed in TNBC and promotes proliferation and metastasis.
- LRPPRC upregulates mitochondrial gene expression, enhancing OXPHOS.
- Gossypol acetate (GAA) binds LRPPRC, induces degradation, and inhibits OXPHOS.
- GAA treatment suppressed TNBC cell proliferation, metastasis, and tumor formation in vivo.
Conclusions:
- A novel pathway involving nuclear gene LRPPRC upregulating mitochondrial gene expression and OXPHOS in TNBC was identified.
- LRPPRC is a promising therapeutic target for TNBC.
- Gossypol acetate (GAA), a traditional gynecological drug, demonstrates significant antitumor activity against TNBC by targeting LRPPRC and OXPHOS.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...